April 4, 2011

Re: United States Only—Important Information About Vivaglobin^®

Dear Healthcare Professional,

In January 2011, CSL Behring announced its intention to discontinue Vivaglobin^® in the United States by year end. Due to the current delays we are experiencing in Vivaglobin^® supply, we feel it would be disruptive to bring the product back temporarily, only to discontinue it later this year. Therefore, we are writing to inform you that CSL Behring has decided to discontinue Vivaglobin^® in the United States effective today.

If you are a Vivaglobin^® prescriber, consider transitioning patients to Hizentra^®. Hizentra^® is the first and only 20 percent subcutaneous immunoglobulin (SCIg) in the United States that is indicated as replacement therapy for patients with primary humoral immunodeficiency. Please visit www.Hizentra.com to learn more.

CSL Behring is also communicating this discontinuation to patients. For your reference, a letter notifying Vivaglobin^® patients about this discontinuation is enclosed. To maintain the privacy of patients' identities, CSL Behring has engaged a third party, Covance, to assist in communicating this information and, if applicable, transitioning patients to Hizentra with minimal disruption to their treatment.

To help your patients make the transition to Hizentra^®, we are offering a Hizentra sample program. This program is designed to offer Vivaglobin^® patients a one-month supply of Hizentra^® to determine if Hizentra^® is right for them. We encourage you to contact your local CSL Behring sales representative or IgIQ (1-877-355-IgIQ) for information on patient enrollment.

We appreciate the support you have given Vivaglobin^® and look forward to continuing to provide patients with Hizentra^®.

Please see Important Safety Information for Hizentra^® and Vivaglobin^® below, and the enclosed full prescribing information for each product.

As always, we thank you for your continued trust in CSL Behring and in our life-saving therapies.

Sincerely,

Lynne Powell
Senior Vice President
North America Commercial Operations

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra^®, and Immune Globulin Subcutaneous (Human), Vivaglobin^®, are indicated as replacement therapy for patients with primary humoral immunodeficiency (PI). This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Hizentra^® and Vivaglobin^® are contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or their components. Because it contains the stabilizer L-proline, Hizentra^® is also contraindicated in patients with hyperprolinemia. Both treatments are contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra^® and Vivaglobin^® should be administered subcutaneously only. Do not administer intravenously (into a blood vessel).

All IgA-deficient patients with anti-IgA antibodies are at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration of these treatments immediately and treat as medically appropriate.

Hizentra^® and Vivaglobin^® are derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common drug-related adverse reactions with Hizentra^® (observed in 5% or more of subjects in the clinical trial) were local reactions (i.e., swelling, redness, heat, pain, and itching at the injection site), headache, vomiting, pain, and fatigue.

The most common drug-related adverse reactions with Vivaglobin^® (observed in 5% or more of subjects in the clinical trial) were local injection-site reactions (e.g., swelling, redness, and itching), headache, nausea, rash, asthenia, and gastrointestinal disorders.

Aseptic meningitis syndrome (AMS) has been reported to occur infrequently with IVIg treatment and treatment with Vivaglobin^®, and might also occur with Hizentra^®. AMS is usually evidenced within 2 days of administration. Also monitor patients for other reactions reported to occur with IVIg treatment that might also occur with Vivaglobin^® or Hizentra^®, including renal dysfunction/failure, thrombotic events, hemolysis, and transfusion-related acute lung injury (TRALI).

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.

Please read full Prescribing Information for Vivaglobin.
Please read full Prescribing Information for Hizentra.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.